{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:14:16Z","timestamp":1731388456609,"version":"3.28.0"},"posted":{"date-parts":[[2024,5,31]]},"group-title":"In Review","reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,8]]},"abstract":"<title>Abstract<\/title>\n        <p>Background\n Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by increased levels of inflammation that primarily manifests in the joints. Macrophages act as key drivers for the progression of RA, contributing to the perpetuation of chronic inflammation and dysregulation of pro-inflammatory cytokines such as interleukin 1 (IL-1). The goal of this study was to develop a macrophage-based cell therapy for biologic drug delivery in an autoregulated manner.\nMethods\n For proof-of-concept, we developed \u201csmart\u201d macrophages to mitigate the effects of IL-1 by delivering its inhibitor, IL-1 receptor antagonist (IL-1Ra). Bone marrow-derived macrophages were lentivirally transduced with a synthetic gene circuit that uses an NF-\u03baB inducible promoter upstream of either the <italic>Il1rn<\/italic> or firefly luciferase transgenes. Two types of joint like cells were utilized to examine therapeutic protection <italic>in vitro<\/italic>, miPSCs derived cartilage and isolated primary mouse synovial fibroblasts while the K\/BxN mouse model of RA was utilized to examine <italic>in vivo<\/italic> therapeutic protection.\nResults\n These engineered macrophages were able to repeatably produce therapeutic levels of IL-1Ra that could successfully mitigate inflammatory activation in co-culture with both tissue engineered cartilage constructs and synovial fibroblasts. Following injection <italic>in vivo<\/italic>, macrophages homed to sites of inflammation and mitigated disease severity in the K\/BxN mouse model of RA.\nConclusion\n These findings demonstrate the successful development of engineered macrophages that possess the ability for controlled, autoregulated production of IL-1 based on inflammatory signaling such as the NF-\u03baB pathway to mitigate the effects of this cytokine for applications in RA or other inflammatory diseases. This system provides proof of concept for applications in other immune cell types as self-regulating delivery systems for therapeutic applications in a range of diseases.<\/p>","DOI":"10.21203\/rs.3.rs-4385938\/v1","type":"posted-content","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T13:16:06Z","timestamp":1717161366000},"source":"Crossref","is-referenced-by-count":0,"title":["Engineered Self-Regulating Macrophages for Targeted Anti-inflammatory Drug Delivery"],"prefix":"10.21203","author":[{"given":"Molly","family":"Klimak","sequence":"first","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Cimino","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Lenz","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Springer","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Collins","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Harasymowicz","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Xu","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Pham","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Guilak","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"15","key":"ref1","article-title":"Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults, 2005\u20132018","volume":"10","author":"Xu Y","year":"2021","unstructured":"Xu Y, Wu Q. Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults, 2005\u20132018. J Clin Med 10(15) (2021).","journal-title":"J Clin Med"},{"issue":"491","key":"ref2","article-title":"HBEGF(+) macrophages in rheumatoid arthritis induce fibroblast invasiveness","volume":"11","author":"Kuo D","year":"2019","unstructured":"Kuo D, Ding J, Cohn IS, Zhang F, Wei K, Rao DA, Rozo C, Sokhi UK, Shanaj S, Oliver DJ, Echeverria AP, DiCarlo EF, Brenner MB, Bykerk VP, Goodman SM, Raychaudhuri S, Ratsch G, Ivashkiv LB, Donlin LT. HBEGF(+) macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med 11(491) (2019).","journal-title":"Sci Transl Med"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/ar2292","article-title":"Cells of the synovium in rheumatoid arthritis. Chondrocytes","volume":"9","author":"Otero M","year":"2007","unstructured":"Otero M, Goldring MB. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res Ther. 2007;9(5):220.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3831\/KPI.2019.22.029","article-title":"Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery","volume":"22","author":"Kesharwani D","year":"2019","unstructured":"Kesharwani D, Paliwal R, Satapathy T, Das Paul S. Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery. J Pharmacopunct. 2019;22(4):210\u201324.","journal-title":"J Pharmacopunct"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/ard.2009.121657","article-title":"Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis","volume":"69","author":"Schett G","year":"2010","unstructured":"Schett G, Firestein GS. Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis. 2010;69(5):787\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.40504","article-title":"Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis","volume":"70","author":"Falconer J","year":"2018","unstructured":"Falconer J, Murphy AN, Young SP, Clark AR, Tiziani S, Guma M, Buckley CD. Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(7):984\u201399.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy EH","year":"2013","unstructured":"Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9(3):154\u201363.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrrheum.2016.136","article-title":"Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis","volume":"12","author":"Robinson WH","year":"2016","unstructured":"Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, Sokolove J. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580\u201392.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cyto.2014.10.006","article-title":"The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy","volume":"74","author":"Roeleveld DM","year":"2015","unstructured":"Roeleveld DM, Koenders MI. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. Cytokine. 2015;74(1):101\u20137.","journal-title":"Cytokine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.intimp.2018.12.040","article-title":"Study of the adoptive immunotherapy on rheumatoid arthritis with Thymus-derived invariant natural killer T cells","volume":"67","author":"Chen D","year":"2019","unstructured":"Chen D, Liu H, Wang Y, Chen S, Liu J, Li W, Dou H, Hou W, Meng M. Study of the adoptive immunotherapy on rheumatoid arthritis with Thymus-derived invariant natural killer T cells. Int Immunopharmacol. 2019;67:427\u201340.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2014.06.019","article-title":"Osteoarthritis joint pain: the cytokine connection","volume":"70","author":"Miller RE","year":"2014","unstructured":"Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine 70(2) (2014) 185\u2009\u2013\u200993.","journal-title":"Cytokine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.imlet.2016.05.001","article-title":"IL-17\u2009+\u2009CD8\u2009+\u2009T cells: Differentiation, phenotype and role in inflammatory disease","volume":"178","author":"Srenathan U","year":"2016","unstructured":"Srenathan U, Steel K, Taams LS. IL-17\u2009+\u2009CD8\u2009+\u2009T cells: Differentiation, phenotype and role in inflammatory disease. Immunol Lett. 2016;178:20\u20136.","journal-title":"Immunol Lett"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/ar2333","article-title":"Cells of the synovium in rheumatoid arthritis. Macrophages","volume":"9","author":"Kinne RW","year":"2007","unstructured":"Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther. 2007;9(6):224.","journal-title":"Arthritis Res Ther"},{"issue":"3 Suppl","key":"ref14","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/01.rhu.0000130687.75646.44","article-title":"Pathogenesis of rheumatoid arthritis","volume":"10","author":"Weissmann G","year":"2004","unstructured":"Weissmann G. Pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2004;10(3 Suppl):S26\u201331.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cei.13098","article-title":"Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells","volume":"193","author":"Alivernini S","year":"2018","unstructured":"Alivernini S, Tolusso B, Ferraccioli G, Gremese E, Kurowska-Stolarska M, McInnes IB. Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clin Exp Immunol. 2018;193(1):13\u201323.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"ref16","first-page":"183","volume":"46","author":"Firestein GS","year":"2017","unstructured":"Firestein GS, McInnes IB. Immunopathogenesis Rheumatoid Arthritis Immun. 2017;46(2):183\u201396.","journal-title":"Immunopathogenesis Rheumatoid Arthritis Immun"},{"issue":"7771","key":"ref17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41586-019-1471-1","article-title":"Locally renewing resident synovial macrophages provide a protective barrier for the joint","volume":"572","author":"Culemann S","year":"2019","unstructured":"Culemann S, Gruneboom A, Nicolas-Avila JA, Weidner D, Lammle KF, Rothe T, Quintana JA, Kirchner P, Krljanac B, Eberhardt M, Ferrazzi F, Kretzschmar E, Schicht M, Fischer K, Gelse K, Faas M, Pfeifle R, Ackermann JA, Pachowsky M, Renner N, Simon D, Haseloff RF, Ekici AB, Bauerle T, Blasig IE, Vera J, Voehringer D, Kleyer A, Paulsen F, Schett G, Hidalgo A, Kronke G. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature. 2019;572(7771):670\u20135.","journal-title":"Nature"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals M","year":"2007","unstructured":"Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Med (Baltim). 2007;86(4):242\u201351.","journal-title":"Med (Baltim)"},{"issue":"18","key":"ref19","doi-asserted-by":"crossref","first-page":"eaay6391","DOI":"10.1126\/sciadv.aay6391","article-title":"Macrophages of diverse phenotypes drive vascularization of engineered tissues","volume":"6","author":"Graney PL","year":"2020","unstructured":"Graney PL, Ben-Shaul S, Landau S, Bajpai A, Singh B, Eager J, Cohen A, Levenberg S, Spiller KL. Macrophages of diverse phenotypes drive vascularization of engineered tissues. Sci Adv. 2020;6(18):eaay6391.","journal-title":"Sci Adv"},{"issue":"44","key":"ref20","doi-asserted-by":"crossref","first-page":"12514","DOI":"10.1073\/pnas.1613884113","article-title":"Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL\/6 Cas9 transgenic mouse line","volume":"113","author":"Chu VT","year":"2016","unstructured":"Chu VT, Graf R, Wirtz T, Weber T, Favret J, Li X, Petsch K, Tran NT, Sieweke MH, Berek C, Kuhn R, Rajewsky K. Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL\/6 Cas9 transgenic mouse line. Proc Natl Acad Sci U S A. 2016;113(44):12514\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2012.12.011","article-title":"Immunopathogenesis of osteoarthritis","volume":"146","author":"Haseeb A","year":"2013","unstructured":"Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. 2013;146(3):185\u201396.","journal-title":"Clin Immunol"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.joca.2017.02.791","article-title":"ADAMTS and ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'","volume":"25","author":"Yang CY","year":"2017","unstructured":"Yang CY, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'. Osteoarthritis Cartilage. 2017;25(7):1000\u20139.","journal-title":"Osteoarthritis Cartilage"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3389\/fimmu.2019.02759","article-title":"More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis","volume":"10","author":"Gschwandtner M","year":"2019","unstructured":"Gschwandtner M, Derler R, Midwood KS. More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis. Front Immunol. 2019;10:2759.","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2016.01.026","article-title":"Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications","volume":"240","author":"Alvarez MM","year":"2016","unstructured":"Alvarez MM, Liu JC, Trujillo-de Santiago G, Cha BH, Vishwakarma A, Ghaemmaghami AM, Khademhosseini A. Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications. J Control Release. 2016;240:349\u201363.","journal-title":"J Control Release"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/1735-5362.272534","article-title":"Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis","volume":"14","author":"Emami J","year":"2019","unstructured":"Emami J, Ansarypour Z. Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis. Res Pharm Sci. 2019;14(6):471\u201387.","journal-title":"Res Pharm Sci"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","article-title":"Anakinra for the treatment of rheumatoid arthritis: a safety evaluation","volume":"17","author":"Ramirez J","year":"2018","unstructured":"Ramirez J, Canete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17(7):727\u201332.","journal-title":"Expert Opin Drug Saf"},{"year":"2016","author":"Gottenberg JE","key":"ref27","unstructured":"Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Liote F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial, JAMA 316(11) (2016) 1172\u20131180."},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier X","year":"2009","unstructured":"Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61(3):344\u201352.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/hum.2017.181","article-title":"Gene Delivery to Joints by Intra-Articular Injection","volume":"29","author":"Evans CH","year":"2018","unstructured":"Evans CH, Ghivizzani SC, Robbins PD. Gene Delivery to Joints by Intra-Articular Injection. Hum Gene Ther. 2018;29(1):2\u201314.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/hum.2008.075","article-title":"Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis","volume":"20","author":"Wehling P","year":"2009","unstructured":"Wehling P, Reinecke J, Baltzer AW, Granrath M, Schulitz KP, Schultz C, Krauspe R, Whiteside TW, Elder E, Ghivizzani SC, Robbins PD, Evans CH. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009;20(2):97\u2013101.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"R134","DOI":"10.1186\/ar4591","article-title":"Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis","volume":"16","author":"Furman BD","year":"2014","unstructured":"Furman BD, Mangiapani DS, Zeitler E, Bailey KN, Horne PH, Huebner JL, Kraus VB, Guilak F, Olson SA. Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. Arthritis Res Ther. 2014;16(3):R134.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-009-0872-0","article-title":"Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study","volume":"29","author":"Fioravanti A","year":"2009","unstructured":"Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int. 2009;29(8):961\u20135.","journal-title":"Rheumatol Int"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/ard.2006.053272","article-title":"Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade","volume":"65","author":"Grunke M","year":"2006","unstructured":"Grunke M, Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis. 2006;65(4):555\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"ref34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512307","article-title":"Circadian Regulation of Macrophages and Osteoclasts in Rheumatoid Arthritis","volume":"24","author":"Kikyo N","year":"2023","unstructured":"Kikyo N. Circadian Regulation of Macrophages and Osteoclasts in Rheumatoid Arthritis. Int J Mol Sci 24(15) (2023).","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2018-213454","article-title":"Gene editing for inflammatory disorders","volume":"78","author":"Ewart DT","year":"2019","unstructured":"Ewart DT, Peterson EJ, Steer CJ. Gene editing for inflammatory disorders. Ann Rheum Dis. 2019;78(1):6\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/jor.24304","article-title":"Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies","volume":"37","author":"Guilak F","year":"2019","unstructured":"Guilak F, Pferdehirt L, Ross AK, Choi Y-R, Collins K, Nims RJ, Katz DB, Klimak M, Tabbaa S, Pham CTN. Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies. J Orthop Res. 2019;37(6):1287\u201393.","journal-title":"J Orthop Res"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08923973.2018.1437625","article-title":"CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis","volume":"40","author":"Safari F","year":"2018","unstructured":"Safari F, Farajnia S, Arya M, Zarredar H, Nasrolahi A. CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis. Immunopharmacol Immunotoxicol. 2018;40(3):201\u201311.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/art.39982","article-title":"CRISPR\/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues","volume":"69","author":"Brunger JM","year":"2017","unstructured":"Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. CRISPR\/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues. Arthritis Rheumatol. 2017;69(5):1111\u201321.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.stemcr.2017.03.022","article-title":"Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs","volume":"8","author":"Brunger JM","year":"2017","unstructured":"Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. Stem Cell Rep. 2017;8(5):1202\u201313.","journal-title":"Stem Cell Rep"},{"issue":"18","key":"ref40","doi-asserted-by":"crossref","first-page":"eaaz6579","DOI":"10.1126\/sciadv.aaz6579","article-title":"Cellular backpacks for macrophage immunotherapy","volume":"6","author":"Shields CWt","year":"2020","unstructured":"Shields CWt, Evans MA, Wang LL, Baugh N, Iyer S, Wu D, Zhao Z, Pusuluri A, Ukidve A, Pan DC, Mitragotri S. Cellular backpacks for macrophage immunotherapy. Sci Adv. 2020;6(18):eaaz6579.","journal-title":"Sci Adv"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fphar.2019.00022","article-title":"Harnessing Macrophages for Controlled-Release Drug Delivery: Lessons From Microbes","volume":"10","author":"Visser JG","year":"2019","unstructured":"Visser JG, Van Staden ADP, Smith C. Harnessing Macrophages for Controlled-Release Drug Delivery: Lessons From Microbes. Front Pharmacol. 2019;10:22.","journal-title":"Front Pharmacol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/ten.tea.2019.0027","article-title":"A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues","volume":"25","author":"Pferdehirt LR","year":"2019","unstructured":"Pferdehirt LR, Brunger AK, Jonathan M., and, Guilak F. A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues. Tissue Eng Part A. 2019;25:809\u201320.","journal-title":"Tissue Eng Part A"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3892\/br.2016.708","article-title":"A protocol for the culture and isolation of murine synovial fibroblasts","volume":"5","author":"Zhao J","year":"2016","unstructured":"Zhao J, Ouyang Q, Hu Z, Huang Q, Wu J, Wang R, Yang M. A protocol for the culture and isolation of murine synovial fibroblasts. Biomed Rep. 2016;5(2):171\u20135.","journal-title":"Biomed Rep"},{"key":"ref44","article-title":"A standardized protocol for the isolation and culture of normal and arthritogenic murine synovial fibroblasts","author":"Armaka M","year":"2009","unstructured":"Armaka M, Gkretsi V, Kontoyiannis D, Kollias G. A standardized protocol for the isolation and culture of normal and arthritogenic murine synovial fibroblasts. Protoc Exch (2009).","journal-title":"Protoc Exch"},{"issue":"47","key":"ref45","doi-asserted-by":"crossref","first-page":"19172","DOI":"10.1073\/pnas.1210422109","article-title":"Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells","volume":"109","author":"Diekman BO","year":"2012","unstructured":"Diekman BO, Christoforou N, Willard VP, Sun H, Sanchez-Adams J, Leong KW, Guilak F. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012;109(47):19172\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1038\/s41598-018-21184-5","article-title":"Early Changes of Articular Cartilage and Subchondral Bone in The DMM Mouse Model of Osteoarthritis","volume":"8","author":"Fang H","year":"2018","unstructured":"Fang H, Huang L, Welch I, Norley C, Holdsworth DW, Beier F, Cai D. Early Changes of Articular Cartilage and Subchondral Bone in The DMM Mouse Model of Osteoarthritis. Sci Rep. 2018;8(1):2855.","journal-title":"Sci Rep"},{"year":"2008","author":"Monach PA","key":"ref47","unstructured":"Monach PA, Mathis D, Benoist C. The K\/BxN arthritis model, Curr Protoc Immunol Chap. 15 (2008) 15 22 1\u201315 22 12."},{"key":"ref48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2016.00213","article-title":"K\/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis","volume":"7","author":"Christensen AD","year":"2016","unstructured":"Christensen AD, Haase C, Cook AD, Hamilton JA. K\/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis. Front Immunol. 2016;7:213.","journal-title":"Front Immunol"},{"issue":"36","key":"ref49","doi-asserted-by":"crossref","first-page":"eabj1414","DOI":"10.1126\/sciadv.abj1414","article-title":"A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery","volume":"7","author":"Choi Y-R","year":"2021","unstructured":"Choi Y-R, Collins KH, Springer LE, Pferdehirt L, Ross AK, Wu C-L, Moutos FT, Harasymowicz NS, Brunger JM, Pham CTN, Guilak F. A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery. Sci Adv. 2021;7(36):eabj1414.","journal-title":"Sci Adv"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/art.38780","article-title":"Use of cartilage derived from murine induced pluripotent stem cells for osteoarthritis drug screening","volume":"66","author":"Willard VP","year":"2014","unstructured":"Willard VP, Diekman BO, Sanchez-Adams J, Christoforou N, Leong KW, Guilak F. Use of cartilage derived from murine induced pluripotent stem cells for osteoarthritis drug screening. Arthritis Rheumatol. 2014;66(11):3062\u201372.","journal-title":"Arthritis Rheumatol"},{"key":"ref51","first-page":"485","article-title":"Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project, Biologics: Targets and Therapy","author":"Thaler K","year":"2009","unstructured":"Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project, Biologics: Targets and Therapy (2009) 485\u201398."},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00281-003-0131-5","article-title":"The KRN mouse model of inflammatory arthritis","volume":"25","author":"Kyburz D","year":"2003","unstructured":"Kyburz D, Corr M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol. 2003;25(1):79\u201390.","journal-title":"Springer Semin Immunopathol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.2147\/IJN.S298159","article-title":"Recent Advances in Macrophage-Mediated Drug Delivery Systems","volume":"16","author":"Liang T","year":"2021","unstructured":"Liang T, Zhang R, Liu X, Ding Q, Wu S, Li C, Lin Y, Ye Y, Zhong Z, Zhou M. Recent Advances in Macrophage-Mediated Drug Delivery Systems. Int J Nanomed. 2021;16:2703\u201314.","journal-title":"Int J Nanomed"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0021-9258(17)49941-8","article-title":"PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis","volume":"295","author":"Powers NE","year":"2020","unstructured":"Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK 3rd, Skerra A, Dinarello CA. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. J Biol Chem. 2020;295(3):868\u201382.","journal-title":"J Biol Chem"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jor.22334","article-title":"Synovial fluid concentrations and relative potency of interleukin-1 alpha and beta in cartilage and meniscus degradation","volume":"31","author":"McNulty AL","year":"2013","unstructured":"McNulty AL, Rothfusz NE, Leddy HA, Guilak F. Synovial fluid concentrations and relative potency of interleukin-1 alpha and beta in cartilage and meniscus degradation. J Orthop Res. 2013;31(7):1039\u201345.","journal-title":"J Orthop Res"},{"issue":"21","key":"ref56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215027","article-title":"Synovial Fluid Cytokines, Chemokines and MMP Levels in Osteoarthritis Patients with Knee Pain Display a Profile Similar to Many Rheumatoid Arthritis Patients","volume":"10","author":"Meehan RT","year":"2021","unstructured":"Meehan RT, Regan EA, Hoffman ED, Wolf ML, Gill MT, Crooks JL, Parmar PJ, Scheuring RA, Hill JC, Pacheco KA, Knight V. Synovial Fluid Cytokines, Chemokines and MMP Levels in Osteoarthritis Patients with Knee Pain Display a Profile Similar to Many Rheumatoid Arthritis Patients. J Clin Med 10(21) (2021).","journal-title":"J Clin Med"},{"issue":"1","key":"ref57","article-title":"Ferraz-Amaro, Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis","volume":"13","author":"Almeida-Santiago C","year":"2022","unstructured":"Almeida-Santiago C, Quevedo-Abeledo JC, Hernandez-Hernandez MV, de Vera-Gonzalez A, Gonzalez-Delgado A, Gonzalez-Gay MA. I. Ferraz-Amaro, Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis. Life (Basel) 13(1) (2022).","journal-title":"Life (Basel)"},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-019-2003-y","article-title":"Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture","volume":"21","author":"Mehta S","year":"2019","unstructured":"Mehta S, Akhtar S, Porter RM, Onnerfjord P, Bajpayee AG. Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture. Arthritis Res Ther. 2019;21(1):238.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"ref59","doi-asserted-by":"crossref","first-page":"11546","DOI":"10.1096\/fj.202000889R","article-title":"The miRNA-mRNA interactome of murine induced pluripotent stem cell-derived chondrocytes in response to inflammatory cytokines","volume":"34","author":"Ross AK","year":"2020","unstructured":"Ross AK, Coutinho de Almeida R, Ramos YFM, Li J, Meulenbelt I, Guilak F. The miRNA-mRNA interactome of murine induced pluripotent stem cell-derived chondrocytes in response to inflammatory cytokines. FASEB J. 2020;34(9):11546\u201361.","journal-title":"FASEB J"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"715894","DOI":"10.3389\/fimmu.2021.715894","article-title":"Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation","volume":"12","author":"Kemble S","year":"2021","unstructured":"Kemble S, Croft AP. Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. Front Immunol. 2021;12:715894.","journal-title":"Front Immunol"},{"issue":"6","key":"ref61","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"Broeder AA","year":"2006","unstructured":"den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006;65(6):760\u20132.","journal-title":"Ann Rheum Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4385938\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4385938\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:10:06Z","timestamp":1731341406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4385938\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":61,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4385938\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13075-024-03425-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,5,31]]},"subtype":"preprint"}}